TNX-355

TNX-355, a genetically engineered monoclonal antibody that acts on the CD4 receptor, has shown considerable promise. TNX-355 targets a part of the CD4 receptor that is responsible for the shape changes that occur after gp120 binds to the receptor. In a phase 2 study, treatment-experienced patients who received intravenous infusions of TNX-355 plus optimised background therapy for 48 weeks achieved greater viral load suppression and larger CD4 cell increases than those who received a placebo, with no serious side-effects.1

References

  1. Norris D et al. TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at 48 weeks. Sixteenth International AIDS Conference, Toronto, abstract THLB0218, 2006
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.